source
- Sanofi’s immunology reckoning; Lilly acquires in vivo CAR-T biotech; RevMed’s ‘Herceptin moment’; and moreWelcome back to another edition of Endpoints Weekly! We’re doing a little bit of celebrating here at Endpoints, as we took home three Neal Awards, which recognize excellence in B2B journalism. The ...Endpoints · 3mo ago↗ source
- STAT+: FDA to speed up review of three psychedelics as mental health treatmentsTrump's embrace of psychedelics and cannabis is shaking up the GOP’s relationship with mind-altering substances.STAT · 3mo ago↗ source
- STAT+: A biotech VC on what Eli Lilly saw in a struggling cancer startup for $3.2BWhat did Eli Lilly see in a struggling biotech startup that made the pharma giant want to pay billions for it? Bryan Roberts has some answers.